| Released | Contributor | Author | Title | Pages | Price |
| 30-Nov-2009 | Pechala's Reports | Lubomir Pechala | RIGEL PHARMACEUTICALS INC (RIGL=US) - REPORT FOR ACTIVE TRADERS | 4 |
$25 |
| 29-Nov-2009 | Wright Reports |
N/A
| Wright Investors Service Comprehensive Report for Rigel Pharmaceuticals, Inc. | 42 |
$65 |
| 28-Nov-2009 | PriceTarget Research, Inc. |
N/A
| Drug Intelligence Monitor: overall outlook NEUTRAL - 25 new Leaders; 25 new Laggards. | 65 |
$20 |
| 28-Nov-2009 | Standard & Poor's Quantitative Report |
N/A
| Rigel Pharmaceuticals | 6 |
$25 |
| 27-Nov-2009 | Pechala's Reports | Lubomir Pechala | RIGEL PHARMACEUTICALS INC (RIGL=US) 2-weeks forecast | 1 |
$10 |
| 27-Nov-2009 | Pechala's Reports | Frantisek Pechala | RIGEL PHARMACEUTICALS INC (RIGL=US) 12-months forecast | 1 |
$15 |
| 26-Nov-2009 | Ford Investor Services, Inc. |
N/A
| Value Graph: RIGEL PHARMACEUT -- RIGL | 1 |
$4 |
| 26-Nov-2009 | Ford Investor Services, Inc. |
N/A
| Industry Value Graph: BMRN , CRXL , NPSP , PGNX , RIGL , ZGEN -- DRUGS | 3 |
$4 |
| 24-Nov-2009 | Jefferson Research |
N/A
| Jefferson Research Financial Sonar Report. A detailed analysis of the current fundamental performance of RIGEL PHARMACEUTICALS INC including Earnings Quality, Cash Flow Quality, Operating Efficiency, Balance Sheet Quality and Valuation. | 3 |
$20 |
| 24-Nov-2009 | Zacks Investment Research Inc. |
N/A
| RIGEL PHARMCTCL (RIGL) Zacks Company Snapshot | 1 |
$10 |
1.48% Nasdaq 0.00%
Research Reports
